LLYLilly (Eli)

Price

$1,189.68+61%1Y

Log

1M6M1YMAX

1M+0.35%·1Y+61%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value40

Quality97

Momentum65

Growth84

Strongest Quality, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. Our products are sold in approximately 90 countries.

In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR

P/E (TTM)39.9

Market Cap$979.64B

1Y Return+61%

5Y Return+412%

Lilly (Eli) (LLY) reported revenue of $23.0B in Q2 2026 (quarter ended June 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 86% and net income of $7.09B (31% of revenue). For the full year FY2025, revenue was $65.2B (+45% year on year) and net income $20.6B. Its largest product in 2026-Q2 was Cardiometabolic Health at $11.7B, 47% of the disclosed total, just ahead of Mounjaro at 19%.